Juvenile Arthritis

Despite minimal evidence available, authors of the 2020 ACR juvenile idiopathic arthritis guidelines emerged with nearly 50 recommendations, emphasizing early use of biologics, regular immunizations and reduced reliance on corticosteroids.

Advances in understanding of systemic juvenile idiopathic arthritis and adult-onset Still’s disease have elucidated the impact of biologic therapies on these conditions, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Tapering canakinumab in patients with systemic juvenile idiopathic arthritis who achieve remission may be feasible but holding this response may require consistent IL-1 inhibition, according to data published in Arthritis & Rheumatology.

Treatment with canakinumab resulted in rapid, sustained improvements in active systemic juvenile idiopathic arthritis, regardless of whether the patient had a fever at initiation, according to data published in Arthritis & Rheumatology.

A quotidian fever lasting at least 2 weeks is one of the hallmarks of systemic onset juvenile idiopathic arthritis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.

Performing basic clinical observation on patients with temporomandibular joint arthritis is critical to determining whether their disease has improved, worsened or remained the same, according to the Rheumatology Nurses Society president.

A U.S. appeals court has ruled in favor of two patents for Amgen’s etanercept against the biosimilar etanercept-szzs from Novartis’ Sandoz, upholding a prior decision validating claims of patent infringement.

Several rheumatology societies in Europe recommended continuing all immunosuppressant therapies as usual in pediatric patients in the face of the continued spread of COVID-19, due to the increased risk for infection associated with withdrawal and subsequent disease flare, according to a review published in Pediatric Rheumatology.

There is a significant amount of variation and discordance among interpretations of inflammatory and structural lesions in sacroiliac joints among children, according to findings published in Arthritis Care & Research.

The Arthritis Foundation is more than 70 years old, but its newest theme — Live Yes! — is in its infancy. Historically, the organization has zeroed in on key pillars, including access to care, advocacy in government and attention to the often-overlooked juvenile arthritis. Yet, the Foundation also understood the importance of interpersonal connections and support networks to patient well-being: An idea that laid the foundation for an online community that simultaneously educates and empowers patients, while cultivating their input to develop solutions for issues common to the arthritis population.